<DOC>
	<DOC>NCT01484197</DOC>
	<brief_summary>This study will assess the pharmacodynamics, safety, tolerability and pharmacokinetics of two different formulations of indacaterol maleate, both administered via the Concept1 device. The study aims to determine whether the novel formulation has a similar clinical profile as the established formulation.</brief_summary>
	<brief_title>A Study to Evaluate the Effects of Indacaterol Maleate as a New Formulation in the Concept 1 Device</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Male and female patients with asthma Aged 18 or above Patients using inhaled corticosteroid (with or without long acting beta agonist) Patients who demonstrate an increase in FEV1 after inhaling a short acting beta agonist Asthma exacerbations in previous 6 months COPD or other pulmonary disease Excessive use of short acting beta agonists</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Indacaterol</keyword>
	<keyword>QAB149</keyword>
</DOC>